Us Bancorp \De\ Autolus Therapeutics PLC Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Us Bancorp \De\ holds 664 shares of AUTL stock, worth $1,985. This represents 0.0% of its overall portfolio holdings.

Number of Shares

664

Previous 1,382 51.95%

Holding current value

$1,985

Previous $4,000 50.0%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$3.38 - $4.69 $2,426 - $3,367	-718 Reduced 51.95%	664 $2,000
Q2 2024 Aug 06, 2024	SELL	$3.33 - $5.68 $6 - $11	-2 Reduced 0.14%	1,382 $4,000
Q4 2023 Feb 09, 2024	BUY	$2.13 - $6.63 $2,947 - $9,175	1,384 New	1,384 $8,000
Q3 2022 Oct 27, 2022	BUY	$2.04 - $3.76 $15,610 - $28,771	7,652 New	7,652 $16,000
Q2 2022 Aug 01, 2022	SELL	$2.04 - $4.68 $614 - $1,408	-301 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$3.52 - $5.46 $24,189 - $37,521	-6,872 Reduced 95.8%	301 $1,000
Q4 2021 Feb 11, 2022	BUY	$5.1 - $7.0 $13,877 - $19,047	2,721 Added 61.12%	7,173 $37,000
Q3 2021 Nov 10, 2021	BUY	$5.32 - $7.37 $15,295 - $21,188	2,875 Added 182.31%	4,452 $30,000
Q2 2021 Aug 05, 2021	BUY	$4.78 - $7.96 $4,340 - $7,227	908 Added 135.72%	1,577 $11,000
Q1 2021 Apr 28, 2021	BUY	$5.49 - $9.36 $713 - $1,216	130 Added 24.12%	669 $4,000
Q4 2020 Feb 04, 2021	SELL	$8.13 - $12.79 $3,504 - $5,512	-431 Reduced 44.43%	539 $5,000
Q3 2020 Nov 10, 2020	BUY	$11.64 - $16.3 $5,878 - $8,231	505 Added 108.6%	970 $11,000
Q2 2020 Aug 07, 2020	SELL	$5.38 - $16.14 $5,944 - $17,834	-1,105 Reduced 70.38%	465 $8,000
Q1 2020 May 13, 2020	BUY	$4.2 - $13.0 $5,577 - $17,264	1,328 Added 548.76%	1,570 $10,000
Q4 2019 Feb 04, 2020	BUY	$11.13 - $16.28 $2,693 - $3,939	242 New	242 $3,000

Others Institutions Holding AUTL

# of Institutions

104

Shares Held

163M

Call Options Held

2.8K

Put Options Held

13.4K

View Full List

About Autolus Therapeutics plc

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $272M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

More about AUTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account